

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/788,606-Conf. #9642
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
				Examiner Name	Xie, Xiaozhen
Sheet	1	of	2	Attorney Docket Number	31173/40002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A45	US-2004/0023356	02-05-2004	Krumlauf et al.	
	A46	US-2007/0292444	12-20-2007	Krumlauf et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C156	Eli Lilly Statement of Grounds of Appeal, Opposition to European Patent Application No. 1133558 B1, dated September 28, 2009.	
	C157	Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Prof. Dr. Thomas Muller, dated September 23, 2009.	
	C158	Winkler et al., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist, <i>EMBO J.</i> 22(23): 6267-76 (2003).	
	C159	van Bezooijen et al., SOST/sclerostin, an osteocyte-derived negative regulator of bone formation, <i>Cytokine Growth Factor Rev.</i> , 16: 319-27 (2005).	
	C160	van Bezooijen et al., Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation, <i>J. Bone Min. Res.</i> 22: 19-28 (2007).	
	C161	van Bezooijen et al., Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist, <i>J. Exp. Med.</i> 199(6): 805-14 (2004).	
	C162	Li et al., Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling, <i>J. Biol. Chem.</i> 280(20): 19883-7 (2005).	
	C163	Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Dr. Walter Sebald, dated September 24, 2009.	
	C164	Kirsch et al., BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPRII, <i>EMBO J.</i> 19(13): 3314-24 (2000).	
	C165	Heinecke et al., Receptor oligomerization and beyond: A case study in bone morphogenetic proteins, <i>BMC Biol.</i> 7: 59 (2009).	
	C166	Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Prof. Dr. Edgar Wingender, dated September 24, 2009.	
	C167	Mayer et al., Differentiation of osteogenetic cells: Systems and regulators, <i>Z. Orthop.</i> , 130: 276-84 (1992) - ABSTRACT ONLY.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/788,606-Conf. #9642
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
				Examiner Name	Xie, Xiaozhen
Sheet	2	of	2	Attorney Docket Number	31173/40002

	C168	Blum et al., Study plan for German students in the summer of 1998, University Bioinformatik lecture announcement (1998).	
	C169	Baxevanis (Ed.) et al., Bioinformatics: A practical guide to the analysis of genes and proteins, John Wiley & Sons, Inc. page 234 (1998).	
	C170	Bishop (Ed.), Guide to Human Genome Computing, Second Edition, Academic Press, Chapter 1: Introduction to human genome computer via the world wide web, pages 1-14 (2003).	
	C171	Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Dr. Auristela Freire de Paes Alves, Ph.D., dated September 9, 2009.	
	C172	Eli Lilly, Biacore experiment comparison results, Setup assay to measure BMP binding to captured SOST, referenced on page 41 of reference C193 dated September 28, 2009.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--